Answers are grounded in this paper and cite their sources.
Toxoplasma gondii prevalence is due, in part, to its ability to persist in hosts while retaining the capacity to transmit and recrudesce. This process, while critical, is poorly understood. Through single cell RNA profiling of in vivo-derived bradyzoites, we show that bradyzoites are heterogeneous and not G1-arrested, as expected from in vitro studies. Instead, they progress through two distinct cell cycles that branch from a single G1 state. One is common amongst tachyzoites and in vitro- and in vivo-derived bradyzoites; the other is newly identified within the population of in vivo-derived bradyzoites. While in G1b, these in vivo-derived bradyzoites express cyst wall proteins predicted to replenish the wall that protects cysts and prevents clearance. We demonstrate that AP2XI-6, a putative AP2-transcription factor expressed by bradyzoites in G1 in vivo, is dispensable for tachyzoite growth and cyst formation in vitro but necessary for encystation or persistence in vivo. We propose that AP2XI-6 is a driver of replication through the newly identified in vivo bradyzoite specific cell cycle and that this is required for cyst maturation or persistence. Authors show mature chronic-stage T. gondii adopt cell-cycle-controlled cyst-wall protein expression and two cell-cycle architectures in vivo. AP2XI-6 is required for the mature architecture; without it, parasites form cysts in vitro but fail in vivo.
No takes yet. Share an insight, caveat, or question.
A 2026 study studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: